An inflammation based score can optimize the selection of patients with advanced cancer considered for early phase clinical trials

PLoS ONE

Volumn 9, Issue 1, 2014, Pages

  Pinato, David J ^a   Stavraka, Chara ^a   Flynn, Michael J ^b   Forster, Martin D ^b   O'Cathail, Séan M ^c   Seckl, Michael J ^c   Kristeleit, Rebecca S ^b   Olmos, David ^d   Turnbull, Samantha J ^b   Blagden, Sarah P ^b  

^a HAMMERSMITH HOSPITAL   (United Kingdom)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

^c IMPERIAL COLLEGE LONDON   (United Kingdom)

^d ROYAL MARSDEN HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMIN; FLUORODEOXYGLUCOSE F 18; HEMOGLOBIN; LACTATE DEHYDROGENASE;

ADULT; ADVANCED CANCER; AGED; AREA UNDER THE CURVE; ARTICLE; BONE METASTASIS; CANCER MORTALITY; CANCER PROGNOSIS; COHORT ANALYSIS; COMPUTER ASSISTED EMISSION TOMOGRAPHY; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST ACCURACY STUDY; FEMALE; HEALTH STATUS; HUMAN; HYPOALBUMINEMIA; INFLAMMATION; INTERMETHOD COMPARISON; LIVER METASTASIS; LUNG METASTASIS; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; NEUTROPHIL LYMPHOCYTE RATIO; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PLATELET TO LYMPHOCYTE RATIO; PREDICTION; PROCESS OPTIMIZATION; PROGRESSION FREE SURVIVAL; RATING SCALE; RECEIVER OPERATING CHARACTERISTIC; RETROSPECTIVE STUDY; RISK ASSESSMENT; SCORING SYSTEM; SEX DIFFERENCE; SURVIVAL TIME; UNIVARIATE ANALYSIS; VISCERAL METASTASIS;

AGED; AGED, 80 AND OVER; BLOOD PLATELETS; CLINICAL TRIALS AS TOPIC; FEMALE; HUMANS; INFLAMMATION; LEUKOCYTE COUNT; LYMPHOCYTES; MALE; MIDDLE AGED; NEOPLASM METASTASIS; NEOPLASM STAGING; NEOPLASMS; NEUTROPHILS; PATIENT SELECTION; PLATELET COUNT; PROGNOSIS; REPRODUCIBILITY OF RESULTS; RETROSPECTIVE STUDIES; TREATMENT OUTCOME; TUMOR BURDEN;

EID: 84897004941     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0083279     Document Type: Article

References (42)

1. Wheler J, Tsimberidou AM, Hong D, Naing A, Jackson T, et al. (2009) Survival of patients in a Phase 1 Clinic: the M. D. Anderson Cancer Center experience. Cancer 115: 1091-1099.
2. Penel N, Clisant S, Lefebvre JL, Adenis A (2009) "Sufficient life expectancy": an amazing inclusion criterion in cancer phase II-III trials. J Clin Oncol 27: e105.
3. Blagden SP, Charman SC, Sharples LD, Magee LR, Gilligan D (2003) Performance status score: do patients and their oncologists agree? Br J Cancer 89: 1022-1027. (Pubitemid 37239205)
4. Ploquin A, Olmos D, Ferte C, Cassier PA, Kramar A, et al. (2012) Lifeexpectancy of patients enrolled in phase 1 clinical trials: A systematic review of published prognostic models. Crit Rev Oncol Hematol.
5. Penel N, Delord JP, Bonneterre ME, Bachelot T, Ray-Coquard I, et al. (2010) Development and validation of a model that predicts early death among cancer patients participating in phase I clinical trials investigating cytotoxics. Invest New Drugs 28: 76-82.
6. Yamamoto N, Tamura T, Fukuoka M, Saijo N (1999) Survival and prognostic factors in lung cancer patients treated in phase I trials: Japanese experience. Int J Oncol 15: 737-741.
7. Arkenau HT, Olmos D, Ang JE, de Bono J, Judson I, et al. (2008) Clinical outcome and prognostic factors for patients treated within the context of a phase I study: the Royal Marsden Hospital experience. Br J Cancer 98: 1029-1033. (Pubitemid 351399798)
8. Arkenau HT, Olmos D, Ang JE, Barriuso J, Karavasilis V, et al. (2008) 90-Days mortality rate in patients treated within the context of a phase-I trial: how should we identify patients who should not go on trial? Eur J Cancer 44: 1536-1540.
9. Stavraka C, Pinato DJ, Turnbull SJ, Flynn MJ, Forster MD, et al. (2013) Developing an objective marker to optimize patient selection and predict survival benefit in early-phase cancer trials. Cancer doi: 10.1002/cncr.28381
10. Olmos D, Ang JE, Gomez-Roca C, Morales-Barrera R, Vulink AJ, et al. (2012) Pitfalls and limitations of a single-centre, retrospectively derived prognostic score for Phase I oncology trial participants - Reply to Fussenich et al.: A new, simple and objective prognostic score for Phase I cancer patients. Eur J Cancer 48:594-596.
11. Chau NG, Florescu A, Chan KK, Wang L, Chen EX, et al. (2011) Early mortality and overall survival in oncology phase I trial participants: can we improve patient selection? BMC Cancer 11: 426.
12. Italiano A, Massard C, Bahleda R, Vataire AL, Deutsch E, et al. (2008) Treatment outcome and survival in participants of phase I oncology trials carried out from 2003 to 2006 at Institut Gustave Roussy. Ann Oncol 19: 787-792. (Pubitemid 351467383)
13. Ho J, Pond GR, Newman C, Maclean M, Chen EX, et al. (2006) Barriers in phase I cancer clinical trials referrals and enrollment: five-year experience at the Princess Margaret Hospital. BMC Cancer 6: 263.
14. Parulekar WR, Eisenhauer EA (2004) Phase I trial design for solid tumor studies of targeted, non-cytotoxic agents: theory and practice. J Natl Cancer Inst 96:990-997. (Pubitemid 39162641)
15. Coussens LM, Werb Z (2002) Inflammation and cancer. Nature 420: 860-867. (Pubitemid 36019639)
16. Mantovani A, Allavena P, Sica A, Balkwill F (2008) Cancer-related inflammation. Nature 454: 436-444.
17. Esper DH, Harb WA (2005) The cancer cachexia syndrome: a review of metabolic and clinical manifestations. Nutr Clin Pract 20: 369-376. (Pubitemid 47050807)
18. Moore MM, Chua W, Charles KA, Clarke SJ (2010) Inflammation and cancer: causes and consequences. Clin Pharmacol Ther 87: 504-508.
19. McMillan DC (2009) Systemic inflammation, nutritional status and survival in patients with cancer. Curr Opin Clin Nutr Metab Care 12: 223-226.
20. Proctor MJ, Morrison DS, Talwar D, Balmer SM, Fletcher CD, et al. (2011) A comparison of inflammation-based prognostic scores in patients with cancer. A Glasgow Inflammation Outcome Study. Eur J Cancer Nov;47(17):2633-41.
21. Pinato DJ, Sharma R (2012) An inflammation-based prognostic index predicts survival advantage after transarterial chemoembolization in hepatocellular carcinoma. Translational Research. Aug;160(2):146-52.
22. Aliustaoglu M, Bilici A, Seker M, Dane F, Gocun M, et al. (2010) The association of pre-treatment peripheral blood markers with survival in patients with pancreatic cancer. Hepatogastroenterology 57: 640-645.
23. Kao SC, Pavlakis N, Harvie R, Vardy JL, Boyer MJ, et al. (2010) High blood neutrophil-to-lymphocyte ratio is an indicator of poor prognosis in malignant mesothelioma patients undergoing systemic therapy. Clin Cancer Res 16: 5805-5813.
24. Alison MR, Nicholson LJ, Lin WR (2011) Chronic inflammation and hepatocellular carcinoma. Recent Results Cancer Res 185: 135-148.
25. Pinato DJ, Stebbing J, Ishizuka M, Khan SA, Wasan HS, et al. (2012) A novel and validated prognostic index in hepatocellular carcinoma: the inflammation based index (IBI). J Hepatol 57: 1013-1020.
26. Pinato DJ, Mauri FA, Ramakrishnan R, Wahab L, Lloyd T, et al. (2012) Inflammation-based prognostic indices in malignant pleural mesothelioma. J Thorac Oncol 7: 587-594.
27. Team RDC (2010) R: A language and environment for statistical computing. In: Computing RFfS, editor. Vienna, Austria.
28. Harrell FE (2010) rms: Regression Modeling Strategies. R package version 3.0-0. ed.
29. Chua W, Clarke SJ, Charles KA (2012) Systemic inflammation and prediction of chemotherapy outcomes in patients receiving docetaxel for advanced cancer. Support Care Cancer 20: 1869-1874.
30. Chua W, Charles KA, Baracos VE, Clarke SJ (2011) Neutrophil/lymphocyte ratio predicts chemotherapy outcomes in patients with advanced colorectal cancer. Br J Cancer 104: 1288-1295.
31. Guthrie GJ, Charles KA, Roxburgh CS, Horgan PG, McMillan DC, et al. (2013) The systemic inflammation-based neutrophil-lymphocyte ratio: Experience in patients with cancer. Crit Rev Oncol Hematol 2013 Oct;88(1):218-30.
32. McMillan DC (2013) The systemic inflammation-based Glasgow Prognostic Score: a decade of experience in patients with cancer. Cancer Treat Rev 39:534-540.
33. Ray-Coquard I, Cropet C, Van Glabbeke M, Sebban C, Le Cesne A, et al. (2009) Lymphopenia as a prognostic factor for overall survival in advanced carcinomas, sarcomas, and lymphomas. Cancer Res 69: 5383-5391.
34. Erdman SE, Poutahidis T (2010) Cancer inflammation and regulatory T cells. Int J Cancer 127: 768-779.
35. Penel N, Vanseymortier M, Bonneterre ME, Clisant S, Dansin E, et al. (2008) Prognostic factors among cancer patients with good performance status screened for phase I trials. Invest New Drugs 26: 53-58.
36. Berasain C, Castillo J, Perugorria MJ, Latasa MU, Prieto J, et al. (2009) Inflammation and liver cancer: new molecular links. Ann N Y Acad Sci 1155:206-221.
37. Han C, Braybrooke JP, Deplanque G, Taylor M, Mackintosh D, et al. (2003) Comparison of prognostic factors in patients in phase I trials of cytotoxic drugs vs new noncytotoxic agents. Br J Cancer 89: 1166-1171. (Pubitemid 37363397)
38. Simon RM, Subramanian J, Li MC, Menezes S (2011) Using cross-validation to evaluate predictive accuracy of survival risk classifiers based on high-dimensional data. Brief Bioinform 12: 203-214.
39. Olmos D, A'Hern R P, Marsoni S, Morales R, Gomez-Roca C, et al. (2012) Patient selection for oncology phase I trials: a multi-institutional study of prognostic factors. J Clin Oncol 30: 996-1004.
40. Rivory LP, Slaviero KA, Clarke SJ (2002) Hepatic cytochrome P450 3A drug metabolism is reduced in cancer patients who have an acute-phase response. Br J Cancer 87: 277-280.
41. Murry DJ, Riva L, Poplack DG (1998) Impact of nutrition on pharmacokinetics of anti-neoplastic agents. Int J Cancer Suppl 11: 48-51.
42. Karavasilis V, Digue L, Arkenau T, Eaton D, Stapleton S, et al. (2008) Identification of factors limiting patient recruitment into phase I trials: a study from the Royal Marsden Hospital. Eur J Cancer 44: 978-982.